Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18151630 | 0.85 | HDAC3 (0.58) | RAB9ANPC1CTDSP1ALDH1A1LMNA | |
| SCHEMBL5612077 | 0.76 | DRD2 (0.64) | RAB9ANPC1CTDSP1HDAC3HDAC1 | |
| SCHEMBL31030773 | 0.75 | RAB9A (0.60) | RAB9ANPC1CTDSP1ALDH1A1LMNA | |
| SCHEMBL1556345 | 0.74 | NAAA (0.54) | RAB9ANPC1ALDH1A1HDAC3HDAC1 | |
| SCHEMBL11212751 | 0.74 | HDAC3 (0.49) | RAB9ANPC1HDAC3HDAC1HDAC2 | |
| SCHEMBL1416822 | 0.73 | NAAA (0.57) | RAB9ANPC1ALDH1A1HDAC3HDAC1 | |
| SCHEMBL1742301 | 0.72 | NPC1 (0.60) | RAB9ANPC1CTDSP1LMNAHDAC3 | |
| SCHEMBL1416655 | 0.70 | RAB9A (0.49) | RAB9ANPC1ALDH1A1LMNAHDAC3 | |
| SCHEMBL692328 | 0.70 | DRD2 (0.59) | RAB9ANPC1ALDH1A1LMNAHPGD | |
| SCHEMBL2237461 | 0.70 | SMN1; SMN2 (0.52) | RAB9ANPC1CTDSP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346845-B2 | Anionic conjugates of glycosylated bacterial metabolite | GLYCAN BIOSCIENCES LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | Glycosynnovations Pty Ltd (AU) | 2014-10-30 | — | — | US | disclosed |
| US-8791245-B2 | Anionic conjugates of glycosylated bacterial metabolite | Glycan Bioscience LLC (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2421877-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | Glycan Biosciences Pty Ltd (AU) | 2012-02-29 | — | — | EP | disclosed |
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES PTY LTD (AU) | 2011-08-04 | — | — | US | disclosed |
| WO-2010037179-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GLYCAN BIOSCIENCES PTY LTD (AU) | 2010-04-08 | — | — | WO | disclosed |
| US-7067620-B2 | Antibacterial agents | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050171010-A1 | NOVEL ANTIBACTERIAL AGENTS | CUMBERLAND PHARMACEUTICALS INC. | 2005-08-04 | — | — | US | disclosed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| US-6518242-B1 | Derivatives of glycopeptide antibacterial agents | THERAVANCE, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6288055-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS; PYRIDINE DERIVATIVES LINKED BY LIGAND | ADVANCED MEDICINE, INC. | 2001-09-11 | — | — | US | disclosed |
| EP-1083917-A1 | NOVEL ANALGESIC AGENTS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999064038-A1 | NOVEL ANALGESIC AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190233-A1 | ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE | GNE, CD44, FUT5 | RAB9A 945/4885NPC1 2199/4885CTDSP1 2959/4885 |
| US-20050171010-A1 | NOVEL ANTIBACTERIAL AGENTS | ENGASE, GALE, MGAM | RAB9A 2901/4885NPC1 3612/4885CTDSP1 2860/4885 |
| US-20140323422-A1 | Anionic Conjugates of Glycosylated Bacterial Metabolite | GNE, CD44, FUT5 | RAB9A 945/4885NPC1 2199/4885CTDSP1 2959/4885 |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | RAB9A 2783/4885NPC1 3927/4885CTDSP1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.